Our data suggest that NMT1 is a potential therapeutic target in lung carcinomas with mutant KRAS and LKB1 and/or KEAP1 (KL/K)MUT, which are highly aggressive and resistant to current therapies, including immune checkpoint inhibitors (27). Here, KRAS is linked to lung carcinoma.